Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab plus CHOP for DLBCL in Malawi
NCT02660710Phase 2Completed
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Mar 2016
- Primary completion
- Jul 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in diffuse large B-cell lymphoma (DLBCL), sponsored by UNC Lineberger Comprehensive Cancer Center. Started Mar 2016; status: completed.
02
Drugs
rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02660710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02660710.